NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

That’s a really good question.

My guess, since this is a derivative lawsuit that having more plaintiffs is unnecessary nor beneficial to bring the case forward or for the court to make determinations to assess damages or remedies as those are made against the corporation for the benefit of ALL shareholders. It’s possible that more shareholder plaintiffs will just further complicate the case, especially if that subjects them to discovery.

It’s a little like a test case that’s used to challenge the constitutionality of a law before SCOTUS whereby the plaintiff is really just a bit player. It doesn’t matter if the case involves $100 or the entire US economy.